Rakovina Therapeutics Inc. has described dual NAD+ ADP-ribosyltransferase (poly(ADP-ribose) polymerase; PARP) and histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of Ewing sarcoma.
Merck Sharp & Dohme LLC has disclosed diacylglycerol acyltransferase type 2 (DGAT2) inhibitors reported to be useful for the treatment of atherosclerosis, type 2 diabetes, fibrosis, heart failure, hepatic steatosis, hypercholesterolemia, hyperlipidemia and obesity, among others.
Bristol Myers Squibb Co. has identified proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) targeting moiety through a linker reported to be useful for the treatment of cancer.
Atopic dermatitis (AD) is a chronic and highly prevalent skin disorder with multifactorial pathogenesis that includes mast cell (MC) activation as one of the main players.
Almac Discovery Ltd. has nominated a new preclinical candidate molecule, ALM-401, a first-in-class bispecific antibody-drug conjugate (ADC) targeting EGFR/ROR1. It is being developed for the treatment of refractory lung cancer characterized by dual expression of ROR1 and EGFR.
Alpha-1 antitrypsin deficiency (AATD) is a recessive genetic disorder caused by single nucleotide variants (SNV) in the SERPINA1 gene encoding for alpha-1 antitrypsin (AAT), with the most common mutation being the E342K mutation (Z allele) that introduces an amino acid change from glutamic acid (E) coding for M-AAT to a lysine (K) coding for Z-AAT.
Avirmax Biopharma Inc. has received IND approval from the FDA to initiate a phase I/IIa trial for its gene therapy treatment targeting wet age-related macular degeneration (AMD), including polypoidal choroidal vasculopathy (PCV).
Gyre Therapeutics Inc. has announced IND clearance for Gyre Pharmaceuticals’ F-230 tablets by China’s National Medical Products Administration (NMPA). F-230 is a selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension (PAH).
Actym Therapeutics Inc. has obtained IND clearance from the FDA to begin a phase I trial of ACTM-838. The first-in-human study will enroll patients in the U.S. and Australia with advanced solid tumors who have failed prior lines of therapy and have no clinically beneficial treatment options.
Kapoose Creek Bio Corp. has announced the identification and advancement of two lead compounds with potential in neurology, specifically for indications in neurodegeneration and mental health. The compounds, KCB-100 and KCB-200, have shown potent neuroplastic and neuroprotective activity in gold-standard tests of primary neurons.
RSS
